Emerging Roles of Non-Coding Rnas in Modulating the Pi3k/Akt Pathway in Cancer Publisher



Hashemi M^{1, 2} ; Mohandesi Khosroshahi E^{1, 2} ; Asadi S^{1, 2} ; Tanha M³ ; Ghatei Mohseni F¹ ; Abdolmohammad Sagha R¹ ; Taheri E¹ ; Vazayefi P¹ ; Shekarriz H¹ ; Habibi F¹ ; Mortazi S¹ ; Khorrami R⁴ ; Nabavi N⁵ ; Rashidi M^{6, 7} Show All Authors
Source: Non-coding RNA Research Published:2025

Abstract

Cancer progression results from the dysregulation of molecular pathways, each with unique features that can either promote or inhibit tumor growth. The complexity of carcinogenesis makes it challenging for researchers to target all pathways in cancer therapy, emphasizing the importance of focusing on specific pathways for targeted treatment. One such pathway is the PI3K/Akt pathway, which is often overexpressed in cancer. As tumor cells progress, the expression of PI3K/Akt increases, further driving cancer advancement. This study aims to explore how ncRNAs regulate the expression of PI3K/Akt. NcRNAs are found in both the cytoplasm and nucleus, and their functions vary depending on their location. They can bind to the promoters of PI3K or Akt, either reducing or increasing their expression, thus influencing tumorigenesis. The ncRNA/PI3K/Akt axis plays a crucial role in determining cell proliferation, metastasis, epithelial-mesenchymal transition (EMT), and even chemoresistance and radioresistance in human cancers. Anti-tumor compounds can target ncRNAs to modulate the PI3K/Akt axis. Moreover, ncRNAs can regulate the PI3K/Akt pathway both directly and indirectly. © 2024 The Authors